ArticleInternational journal of clinical and experimental medicine2015
PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Mapping prostate cancer pathobiology: A review of genetically engineered mouse models (GEMMs).Gene · 2026Review
- Transcriptional network analysis of PTEN-protein-deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication.Molecular oncology · 2026Article
- Targeting the PI3K/AKT/mTOR signaling pathway in prostate cancer: Molecular dysregulation, therapeutic advances, and future directions.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Intraductal carcinoma of the prostate: A comprehensive literature review focused on grading challenges and controversies.Histology and histopathology · 2025Review
- The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.International journal of molecular sciences · 2025Review
- microRNA 21 and long non-coding RNAs interplays underlie cancer pathophysiology: A narrative review.Non-coding RNA research · 2024Review
- Review
- Molecular complexity of intraductal carcinoma of the prostate.Cancer medicine · 2024Review
- Article
- Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Palmitic acid negatively regulates tumor suppressor PTEN through T366 phosphorylation and protein degradation.Cancer letters · 2021Article
- Review
- Precise Immunodetection of PTEN Protein in Human Neoplasia.Cold Spring Harbor perspectives in medicine · 2019Review
- Review
- Clinical implications of PTEN loss in prostate cancer.Nature reviews. Urology · 2018Review
- Association BetweenCancer diagnosis & prognosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledPTEN (10q23.3) is a negative regulator of the phosphatidylinositol 3-kinase (PIK3)/Akt survival pathway and a tumor suppressor frequently deleted in prostate cancer. PTEN genomic deletion is among the most common genetic aberrations in human prostate cancer. At present, the prognostic value of PTEN genomic deletion is unclear. We performed a systematic review and meta-analysis to clarify the association between PTEN genomic deletion and a higher Gleason score or a higher possibility of capsular penetration. A comprehensive, computerized literature search of PubMed was carried out until May 27, 2014. Studies were included according to specific inclusion criteria. Pooled hazard ratio was estimated using the fixed effects model or random effects model according to heterogeneity between studies. Seven eligible studies meeting the specific inclusion criteria were selected for further analysis; all were retrospective studies. Overall meta-analysis demonstrated that PTEN genomic deletion was associated with a higher Gleason score (OR 0.319; 95% confidence interval: 0.153-0.666; P = 0.000) and a higher possibility of capsular penetration (OR 0.393; 95% confidence interval: 0.185-0.837; P = 0.015). None of the studies materially altered the original results and no evidence of publication bias was found.
conclusionPTEN genomic deletion in operable localized prostate cancer indicates a higher Gleason score and a higher probability of capsular penetration, indicating a worse prognosis. Further studies should be conducted in order to investigate the effect of PTEN genomic deletion on clinical outcomes in different histological types of prostate cancer or its function in castration-resistant prostate cancer.
Indexed as
Identifiers
26131120PMC4483905What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.